85 results
6-K
EX-99.1
ARGX
Argen X SE
26 Mar 24
Regulatory decision in Japan represents first global approval for VYVGART in ITP
6:05am
. By reducing circulating autoantibodies, VYVGART is uniquely designed to serve as a precision intervention that targets the underlying disease biology
6-K
EX-99.1
ARGX
Argen X SE
21 Mar 24
Current report (foreign)
6:07am
the driving force behind our work to pioneer first-in-class targets and is the engine that produced VYVGART, empasiprubart and ARGX-119 as well … with leading disease biologists who are researching first-in-class disease targets or pathways. Our IIP has a track record of success and nine programs
6-K
EX-99.1
ARGX
Argen X SE
29 Feb 24
Current report (foreign)
4:04pm
in this new class of medicine; ARGX-121 and ARGX-220, which are first-in-class targets broadening argenx’s focus across the immune system; and ARGX-109
6-K
EX-99.1
ARGX
Argen X SE
8 Jan 24
Reported $1.2 billion in preliminary* full-year 2023 global net product sales
6:06am
targeting FcRn and further solidifying argenx’s leadership in this new class of medicine; ARGX-121 and ARGX-220, which are first-in-class targets
6-K
EX-99.2
begv2b7
8 Jan 24
Reported $1.2 billion in preliminary* full-year 2023 global net product sales
6:06am
6-K
EX-99.1
26vkl
1 Nov 23
Patients treated with VYVGART experienced consistent improvements on key quality of life measures based on long-term gMG extension data
4:01pm
6-K
EX-99.1
08fknno0s6z2sv9
21 Sep 23
Current report (foreign)
8:38am
424B5
bv74r6d
20 Jul 23
Prospectus supplement for primary offering
4:51pm
424B5
nmz9dxabri7p xda
17 Jul 23
Prospectus supplement for primary offering
4:42pm
6-K
EX-99.2
pqgvgg1ztjqmrti 4hf
17 Jul 23
Current report (foreign)
7:56am
6-K
EX-99.1
dwi05 vfg7z4uijd9xl
5 May 23
Current report (foreign)
8:05am
6-K
EX-99.1
byc6658lmv wbq18pl
17 Apr 23
Current report (foreign)
5:24pm
6-K
EX-99.1
xn02zn1jizxh8ibgwcgf
30 Nov 22
Current report (foreign)
4:02pm
6-K
EX-99.2
ws7qsw3tf3dadubu
21 Sep 22
Current report (foreign)
7:39am
6-K
EX-99.1
5e9e70ahkqg
21 Sep 22
Current report (foreign)
7:39am
6-K
EX-99.1
91jzg1 kl2
12 Aug 22
Current report (foreign)
8:19am
6-K
EX-99.1
n4z68pts7wmyea1u 79
27 Jun 22
Current report (foreign)
6:00am
424B5
k8ctygcclr2y
25 Mar 22
Prospectus supplement for primary offering
4:21pm
424B5
xxmnavj pof
22 Mar 22
Prospectus supplement for primary offering
4:33pm